RE:RE:RE:RE:RE:RE:RE:PMX is worth 9 Bullion all day long!Gorf79 wrote: Your core assumption, in revenue not multiple, is light by a factor of 2 MM.
JMHO
thats the big question
to what extent will an acquirer pay-up for that which, at least on the surface, seems unproven so far?
things like :
- More columns for 50% of patients
- value associated with worldwide rights to EAA
- potential expanded use due to Covid ( endotoxin translocation)
- abilry to change more because of a better than expected mortality benefit
- etc,etc.
perhaps in time these-revenue expanders will be proven ( eg EDEN study, Tigris " exceeding expectations", other RWE, etc)
In which case the valuation should move up as things progress.
MM